女性健康领域正成医药创新核心,2026年以来国内外药企新药/新适应症突破不断。亚虹医药核心产品希维她®获批上市,用于治疗子宫颈上皮内瘤变2级,是非手术无创治疗产品,旨在重塑全球治疗标准;轩竹生物自主研发的轩悦宁®第三个适应症获批,成为中国首个覆盖HR+/HER2-晚期乳腺癌全疗程的CDK4/6抑制剂;石药集团注射用紫杉醇白蛋白纳米粒获FDA批准在美国开展临床试验;百利天恒的iza-bren用于局部...
Source Link女性健康领域正成医药创新核心,2026年以来国内外药企新药/新适应症突破不断。亚虹医药核心产品希维她®获批上市,用于治疗子宫颈上皮内瘤变2级,是非手术无创治疗产品,旨在重塑全球治疗标准;轩竹生物自主研发的轩悦宁®第三个适应症获批,成为中国首个覆盖HR+/HER2-晚期乳腺癌全疗程的CDK4/6抑制剂;石药集团注射用紫杉醇白蛋白纳米粒获FDA批准在美国开展临床试验;百利天恒的iza-bren用于局部...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.